Jonas F Ludvigsson
Jonas F Ludvigsson is an expert in Gastroenterology at Örebro University Hospital (Sweden). As of October 2026, ScienceLeadR ranks Jonas F Ludvigsson in the top 1% of experts worldwide for Malabsorption Syndromes, Colitis and Epidemiologic Studies. Jonas F Ludvigsson has authored 960 publications, the most recent in 2026, and is an investigator in 3 clinical trials. SLR score: 4,147 (community average: 125). How the SLR is computed.
LeadR Profile
Gastroenterology
Subspecialties: Public Health - Hepatology - Pharmacy
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Short Biography
Jonas F. Ludvigsson’s research emanates from a long-standing expertise in Swedish healthcare registers and epidemiology, where he focuses on celiac disease, inflammatory bowel disease (IBD), liver disease, and gastrointestinal cancer. A lot of his research also concerns children. Ludvigsson continues to work clinically three days a week, most often in the pediatric wards.
He has more than 700 scientific publications, including several books.
Ludvigsson is currently the Scientific Secretary of the Swedish Society of Medicine.
In 2024, he received HM. The King of Sweden’s Medal of the 8th size in the Order of the Seraphim ribbon for outstanding research contributions in inflammatory bowel diseases and pediatrics. He is currently the Scientific Secretary of the Swedish Society of Medicine.
Organizations
Career arc: 2002 - 2026
Number : 960
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Risk of Adverse Kidney Outcomes in Families with MASLD: A Population-Based Multigenerational Cohort Study. PMID 42933690 — liver diseases, kidney diseases, incidence, cohort studies, kidney, biopsy, liver, spouses, siblings, risk factors | JHEP Rep | 2026 | 0 |
| Identification of Patients with Colon Ischemia in the Swedish ESPRESSO Cohort: A Validation Study. PMID 42928875 — gastroenterology, colon, systematized nomenclature of medicine, colitis, ischemic, ischemia | Clin Epidemiol | 2026 | 0 |
| Platelet P2Y12 inhibitor use and risk of colorectal cancer incidence and colorectal cancer-related mortality: a Swedish registry-based cohort study. PMID 42870228 — registries, mortality, incidence, neoplasms, cohort studies, aspirin, diagnosis, colorectal neoplasms, blood platelets, gastrointestinal diseases | BMC Gastroenterol | 2026 | 0 |
| Early Colectomy and Long-Term Risk of Cardiometabolic Disease in Ulcerative Colitis: A Nationwide Cohort Study. PMID 42841618 — diabetes mellitus, colitis, gastroenterology, incidence, cohort studies, colitis, ulcerative, colectomy, diabetes mellitus, type 2 | Am J Gastroenterol | 2026 | 0 |
| Vedolizumab vs TNF Antagonists and Long-Term Outcomes in Ulcerative Colitis. PMID 42789265 — colitis, hospitalization, incidence, adrenal cortex hormones, cohort studies, tumor necrosis factor inhibitors, adalimumab, therapeutics, colitis, ulcerative, colectomy, infliximab | JAMA Netw Open | 2026 | 0 |
Clinical Studies 3
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Cohort/Consortium Investigators 3
LeadR Networks
Main global connection map